For Health Catalyst Inc. [HCAT], Citigroup sees a rise to $40. What next?

Health Catalyst Inc. [NASDAQ: HCAT] loss -0.61% or -0.19 points to close at $30.73 with a heavy trading volume of 1346572 shares. The company report on August 24, 2020 that Digital Transformation of Healthcare: CEO’s of ONEM, HCAT, DOCRF, IRTC, Discuss Telemedicine, Big Data, and Diagnostics.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of Health Catalyst, Inc. (NASDAQ:HCAT), CloudMD (OTC: DOCRF), 1Life Healthcare, Inc. (NASDAQ:ONEM), and iRhythm Technologies, Inc. (NASDAQ:IRTC).

Health Catalyst, Inc. (NASDAQ: HCAT) Dan Burton, CEO “Healthcare Analytics in the New Normal” Earnings Call Highlights: https://bit.ly/3aSo0z6.

It opened the trading session at $30.92, the shares rose to $31.85 and dropped to $30.54, the range by which the price of stock traded the whole day. The daily chart for HCAT points out that the company has recorded 1.15% gains over the past six months. However, it is still -75.8% lower than its most recent low trading price.

If we look at the average trading volume of 688.60K shares, HCAT reached to a volume of 1346572 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Health Catalyst Inc. [HCAT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HCAT shares is $38.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HCAT stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Citigroup have made an estimate for Health Catalyst Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 14, 2020. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on June 18, 2020, representing the official price target for Health Catalyst Inc. stock. Previously, the target price had yet another raise to $32, while Evercore ISI analysts kept a Outperform rating on HCAT stock.

The Average True Range (ATR) for Health Catalyst Inc. is set at 1.31, with the Price to Sales ratio for HCAT stock in the period of the last 12 months amounting to 7.24. The Price to Book ratio for the last quarter was 5.00, with the Price to Cash per share for the same quarter was set at 8.74.

Trading performance analysis for HCAT stock

Health Catalyst Inc. [HCAT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.33. With this latest performance, HCAT shares dropped by -14.28% in over the last four-week period, additionally plugging by 1.15% over the last 6 months – not to mention a drop of -23.18% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HCAT stock in for the last two-week period is set at 39.28, with the RSI for the last a single of trading hit 30.97, and the three-weeks RSI is set at 41.91 for Health Catalyst Inc. [HCAT]. The present Moving Average for the last 50 days of trading for this stock 33.19, while it was recorded at 30.95 for the last single week of trading, and 31.19 for the last 200 days.

Health Catalyst Inc. [HCAT]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Health Catalyst Inc. [HCAT] shares currently have an operating margin of -35.12 and a Gross Margin at +45.50. Health Catalyst Inc.’s Net Margin is presently recorded at -38.79.

Return on Total Capital for HCAT is now -34.52, given the latest momentum, and Return on Invested Capital for the company is -38.95. Return on Equity for this stock declined to -50.99, with Return on Assets sitting at -29.08. When it comes to the capital structure of this company, Health Catalyst Inc. [HCAT] has a Total Debt to Total Equity ratio set at 26.25. Additionally, HCAT Total Debt to Total Capital is recorded at 20.79, with Total Debt to Total Assets ending up at 17.42. Long-Term Debt to Equity for the company is recorded at 24.85, with the Long-Term Debt to Total Capital now at 19.68.

Reflecting on the efficiency of the workforce at the company, Health Catalyst Inc. [HCAT] managed to generate an average of -$66,773 per employee. Receivables Turnover for the company is 5.61 with a Total Asset Turnover recorded at a value of 0.75.Health Catalyst Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.90 and a Current Ratio set at 7.90.

Health Catalyst Inc. [HCAT]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Health Catalyst Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HCAT.

An analysis of insider ownership at Health Catalyst Inc. [HCAT]

There are presently around $1,052 million, or 89.20% of HCAT stock, in the hands of institutional investors. The top three institutional holders of HCAT stocks are: NORWEST VENTURE PARTNERS XI, LP with ownership of 2,352,091, which is approximately 0% of the company’s market cap and around 2.50% of the total institutional ownership; NORWEST VENTURE PARTNERS XII, LP, holding 2,352,090 shares of the stock with an approximate value of $72.28 million in HCAT stocks shares; and VANGUARD GROUP INC, currently with $63.39 million in HCAT stock with ownership of nearly 131.038% of the company’s market capitalization.

Positions in Health Catalyst Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 109 institutional holders increased their position in Health Catalyst Inc. [NASDAQ:HCAT] by around 12,911,895 shares. Additionally, 30 investors decreased positions by around 5,752,747 shares, while 11 investors held positions by with 15,561,592 shares. The mentioned changes placed institutional holdings at 34,226,234 shares, according to the latest SEC report filing. HCAT stock had 43 new institutional investments in for a total of 2,786,263 shares, while 14 institutional investors sold positions of 3,910,814 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam